Cixutumumab

Cixutumumab
Cixutumumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1 receptor
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 947687-12-9 N
ATC code None
UNII 2285XW22DR YesY
KEGG D09328 YesY
Chemical data
Formula C6500H10052N1724O2036S44 
Mol. mass 146.3 kDa
 N(what is this?)  (verify)

Cixutumumab is a monoclonal antibody for the treatment of solid tumors.[1][2]

This drug was developed by ImClone Systems Inc. under the name IMC-A12.

It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.[3]

References

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cixutumumab American Medical Association.
  2. ^ McKian, KP; Haluska, P (2009). "Cixutumumab". Expert opinion on investigational drugs 18 (7): 1025–33. doi:10.1517/13543780903055049. PMID 19548856. 
  3. ^ [1] National Cancer InstituteTemplate:Http://www.cancer.gov/drugdictionary/?CdrID=561575
v · d · eMonoclonal antibodies for tumors
Tumor ("-t(u[m])-")
Human ("-tumu-")

Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab

"-melu-" (melanoma): Flanvotumab
Mouse ("-tumo-")

Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8

"-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab

"-pro-" (prostate tumor): Capromab pendetide

"-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatox
Chimeric ("-tuxi-")

Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab

"-mexi-" (melanoma): Ecromeximab
Humanized ("-tuzu-")
Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • Veltuzumab
Rat/mouse hybrid ("-tumaxo-")


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.